We explored the effects of silibinin, a natural flavonoid, on MCF7 breast cancer cells to assess its potential as a treatment option. Using flow cytometry, we discovered that silibinin significantly inhibits cell growth and induces apoptosis in a dose-dependent manner after 24 hours of treatment.
Notably, the study found increased expression of important genes related to apoptosis and cancer suppression, suggesting that silibinin could enhance the effectiveness of traditional chemotherapy. Its low side effects make it an appealing candidate for further research in cancer therapy.
Read More
8
Silybin promotes breast cancer cell death
The apoptotic effects of silibinin on MDA-MB-231 and MCF-7 human breast carcinoma cells.
We explored how silibinin, a component of Silybum marianum, affects breast cancer cells, specifically MDA-MB-231 and MCF-7 types, through rigorous laboratory methods. Both cell lines were treated with silibinin in different settings, and results indicated a significant increase in cell death compared to controls.
The findings revealed that silibinin effectively triggered cell death through specific mechanisms. Although promising, it is essential to note that while silibinin has an impact, its overall therapeutic potential in clinical contexts requires further investigation.
Read More
8
Silibinin reduces breast cancer cell spread
Inhibition of silibinin on migration and adhesion capacity of human highly metastatic breast cancer cell line, MDA-MB-231, by evaluation of β1-integrin and downstream molecules, Cdc42, Raf-1 and D4GDI.
We explored how silibinin, a natural flavonoid from milk thistle, affects the aggressive MDA-MB-231 breast cancer cells. Through a series of tests including migration and adhesion assays, we discovered that silibinin significantly reduces the migration and adhesion of these cancer cells.
While it inhibited the expression of certain critical molecules involved in cancer spread, it did not significantly alter β1-integrin or Raf-1 levels directly. Overall, our findings suggest that silibinin may help reduce the metastatic behavior of breast cancer cells, which is promising for future treatment strategies.
Read More
Most Useful Reviews
9
Liver function normalised
1 people found this helpful
The doctor prescribed the same treatment. My sister, undergoing chemotherapy for breast cancer, had elevated liver enzyme levels after starting her treatment. I informed her this would protect her liver and lower those levels. Eventually, her oncology doctor also prescribed it for her daily use. Her liver function returned to normal and the chemotherapy has been effective for her breast cancer.
Read More
0
Caution advised
3 people found this helpful
I purchased this for its high antioxidant content, which may help with various issues, including hormonal sensitivity related to breast cancer. Though beneficial for conditions like fatty liver, I found that women with such sensitivity should approach it cautiously. Consequently, I've limited my use and left it for the men in my household to help manage blood sugar.
We explored the effects of silibinin, a natural flavonoid, on MCF7 breast cancer cells to assess its potential as a treatment option. Using flow cytometry, we discovered that silibinin significantly inhibits cell growth and induces apoptosis in a dose-dependent manner after 24 hours of treatment.
Notably, the study found increased expression of important genes related to apoptosis and cancer suppression, suggesting that silibinin could enhance the effectiveness of traditional chemotherapy. Its low side effects make it an appealing candidate for further research in cancer therapy.
Oral silymarin formulation efficacy in management of AC-T protocol induced hepatotoxicity in breast cancer patients: A randomized, triple blind, placebo-controlled clinical trial.
We explored the effects of silymarin on liver health in non-metastatic breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide-paclitaxel. In a rigorous randomized trial, 30 participants received either oral silymarin or a placebo.
Our findings revealed that silymarin significantly reduced the severity of liver damage after one month of treatment. This suggests that this natural supplement may offer protective benefits against chemotherapy-induced liver toxicity, making it a valuable addition to cancer care.
Read More
8
Silymarin gel reduces radiodermatitis severity
Topical silymarin administration for prevention of acute radiodermatitis in breast cancer patients: A randomized, double-blind, placebo-controlled clinical trial.
We examined the effect of silymarin gel on protecting the skin of breast cancer patients undergoing radiotherapy. In a randomized, double-blind trial, forty patients applied either 1% silymarin gel or a placebo daily starting the first day of treatment. Over five weeks, we noted that those using silymarin experienced significantly less severe radiodermatitis and a delay in symptom progression compared to the placebo group. Overall, silymarin gel proved helpful in reducing the skin irritation commonly caused by radiation therapy.
Read More
8
Silybin promotes breast cancer cell death
The apoptotic effects of silibinin on MDA-MB-231 and MCF-7 human breast carcinoma cells.
We explored how silibinin, a component of Silybum marianum, affects breast cancer cells, specifically MDA-MB-231 and MCF-7 types, through rigorous laboratory methods. Both cell lines were treated with silibinin in different settings, and results indicated a significant increase in cell death compared to controls.
The findings revealed that silibinin effectively triggered cell death through specific mechanisms. Although promising, it is essential to note that while silibinin has an impact, its overall therapeutic potential in clinical contexts requires further investigation.
Read More
8
Silibinin induces autophagic cell death
Silibinin, a natural flavonoid, induces autophagy via ROS-dependent mitochondrial dysfunction and loss of ATP involving BNIP3 in human MCF7 breast cancer cells.
We explored the effects of silibinin, a compound from milk thistle, on breast cancer cells.
The study revealed that silibinin can induce cell death through a process called autophagy, which was significantly inhibited when specific blockers were used.
It works by increasing harmful reactive oxygen species and disrupting cellular energy production.
Notably, this process involves a protein called BNIP3, which, when silenced, prevented cell death and restored normal function.
The doctor prescribed the same treatment. My sister, undergoing chemotherapy for breast cancer, had elevated liver enzyme levels after starting her treatment. I informed her this would protect her liver and lower those levels. Eventually, her oncology doctor also prescribed it for her daily use. Her liver function returned to normal and the chemotherapy has been effective for her breast cancer.
Read More
0
Caution advised
3 people found this helpful
I purchased this for its high antioxidant content, which may help with various issues, including hormonal sensitivity related to breast cancer. Though beneficial for conditions like fatty liver, I found that women with such sensitivity should approach it cautiously. Consequently, I've limited my use and left it for the men in my household to help manage blood sugar.
Read More
Frequently Asked Questions
No FAQs are available for this product and symptom.
References
Fatemi Shandiz A, Karimi G, Dayyani M, Hosseini S, Elyasi S. Evaluation of oral silymarin formulation efficacy in prevention of doxorubicin induced hepatotoxicity in patients with non-metastatic breast cancer. J Oncol Pharm Pract. 2024. 10.1177/10781552241268778
Moezian GSA, Javadinia SA, Sales SS, Fanipakdel A, Elyasi S, et al. Oral silymarin formulation efficacy in management of AC-T protocol induced hepatotoxicity in breast cancer patients: A randomized, triple blind, placebo-controlled clinical trial. J Oncol Pharm Pract. 2022;28:827. 10.1177/10781552211006182
Karbasforooshan H, Hosseini S, Elyasi S, Fani Pakdel A, Karimi G. Topical silymarin administration for prevention of acute radiodermatitis in breast cancer patients: A randomized, double-blind, placebo-controlled clinical trial. Phytother Res. 2019;33:379. 10.1002/ptr.6231
Bayram D, Çetin ES, Kara M, Özgöçmen M, Candan IA. The apoptotic effects of silibinin on MDA-MB-231 and MCF-7 human breast carcinoma cells. Hum Exp Toxicol. 2017;36:573. 10.1177/0960327116658105
Jiang K, Wang W, Jin X, Wang Z, Ji Z, et al. Silibinin, a natural flavonoid, induces autophagy via ROS-dependent mitochondrial dysfunction and loss of ATP involving BNIP3 in human MCF7 breast cancer cells. Oncol Rep. 2015;33:2711. 10.3892/or.2015.3915
Pirouzpanah MB, Sabzichi M, Pirouzpanah S, Chavoshi H, Samadi N. Silibilin-induces apoptosis in breast cancer cells by modulating p53, p21, Bak and Bcl-XL pathways. Asian Pac J Cancer Prev. 2015;16:2087. PubMed
Kim S, Han J, Kim JS, Kim JH, Choe JH, et al. Silibinin suppresses EGFR ligand-induced CD44 expression through inhibition of EGFR activity in breast cancer cells. Anticancer Res. 2011;31:3767. PubMed
Dastpeyman M, Motamed N, Azadmanesh K, Mostafavi E, Kia V, et al. Inhibition of silibinin on migration and adhesion capacity of human highly metastatic breast cancer cell line, MDA-MB-231, by evaluation of β1-integrin and downstream molecules, Cdc42, Raf-1 and D4GDI. Med Oncol. 2012;29:2512. 10.1007/s12032-011-0113-8
Toxicology and carcinogenesis studies of milk thistle extract (CAS No. 84604-20-6) in F344/N rats and B6C3F1 mice (Feed Studies). Natl Toxicol Program Tech Rep Ser. 2011. PubMed
Kim S, Lee HS, Lee SK, Kim SH, Hur SM, et al. 12-O-Tetradecanoyl phorbol-13-acetate (TPA)-induced growth arrest is increased by silibinin by the down-regulation of cyclin B1 and cdc2 and the up-regulation of p21 expression in MDA-MB231 human breast cancer cells. Phytomedicine. 2010;17:1127. 10.1016/j.phymed.2010.03.013
Wang HJ, Jiang YY, Wei XF, Huang H, Tashiro S, et al. Silibinin induces protective superoxide generation in human breast cancer MCF-7 cells. Free Radic Res. 2010;44:90. 10.3109/10715760903300717
Kim S, Kim SH, Hur SM, Lee SK, Kim WW, et al. Silibinin prevents TPA-induced MMP-9 expression by down-regulation of COX-2 in human breast cancer cells. J Ethnopharmacol. 2009;126:252. 10.1016/j.jep.2009.08.032
Kim S, Choi JH, Lim HI, Lee SK, Kim WW, et al. Silibinin prevents TPA-induced MMP-9 expression and VEGF secretion by inactivation of the Raf/MEK/ERK pathway in MCF-7 human breast cancer cells. Phytomedicine. 2009;16:573. 10.1016/j.phymed.2008.11.006
Verschoyle RD, Brown K, Steward WP, Gescher AJ. Consumption of silibinin, a flavonolignan from milk thistle, and mammary cancer development in the C3(1) SV40 T,t antigen transgenic multiple mammary adenocarcinoma (TAg) mouse. Cancer Chemother Pharmacol. 2008;62:369. PubMed
Provinciali M, Papalini F, Orlando F, Pierpaoli S, Donnini A, et al. Effect of the silybin-phosphatidylcholine complex (IdB 1016) on the development of mammary tumors in HER-2/neu transgenic mice. Cancer Res. 2007;67:2022. PubMed
Lee SO, Jeong YJ, Im HG, Kim CH, Chang YC, et al. Silibinin suppresses PMA-induced MMP-9 expression by blocking the AP-1 activation via MAPK signaling pathways in MCF-7 human breast carcinoma cells. Biochem Biophys Res Commun. 2007;354:165. PubMed